AAPG: Ascentage Pharma Group International insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
8 institutions reported holding $264K of Ascentage Pharma Group International on Form 13F (7 the quarter before). 3 opened a new position and 2 sold out. Shares held by institutions: -50%.
| Largest holders | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 13,841 | $243K |
| MORGAN STANLEY | 919 | $16K |
| WELLS FARGO & COMPANY/MN | 200 | $4K |
| EverSource Wealth Advisors, LLC | 24 | $421 |
| UBS Group AG | 15 | $263 |
| BlackRock, Inc. | 6 | $105 |
| Caitong International Asset Management Co., Ltd | 1 | $18 |
| ROYAL BANK OF CANADA | 6 | - |
Clinical trial readouts
6 Phase 2 or 3 trials by Ascentage Pharma Group International with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-12 (est.) | APG2575 | Chronic Lymphocytic Leukemia | Phase 2 | 75 | Recruiting | NCT05147467 |
| 2026-12-31 (est.) | lisaftoclax +BTK inhibitor | CLL/SLL | Phase 3 | 400 | Recruiting | NCT06104566 |
| 2027-03-31 (est.) | Olverembatinib | GIST | Phase 3 | 40 | Recruiting | NCT06640361 |
| 2027-06-01 (est.) | APG-115 | Neuroblastoma | Phase 1/2 | 100 | Recruiting | NCT05701306 |
| 2027-06-30 (est.) | olverembatinib | Chronic Myeloid Leukemia | Phase 3 | 333 | Recruiting | NCT06423911 |
| 2027-08 (est.) | Lisaftoclax (APG-2575) | CLL/SLL | Phase 3 | 344 | Recruiting | NCT06319456 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.